Soligenix (SNGX) Change in Receivables (2010 - 2024)
Soligenix's (SNGX) quarterly Change in Receivables came in at -$117029.0 in Q2 2024, down 12.26% YoY from -$133375.3 in Q3 2023, and down 115.82% on a QoQ basis from -$54225.0 in Q1 2024.
Soligenix (SNGX) Change in Receivables (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of Change in Receivables data on file, last reported at -$117029.0 in Q2 2024.
- Quarterly Change in Receivables fell 12.26% year-over-year to -$117029.0 in Q2 2024, while the trailing twelve-month figure through Dec 2024 was -$171254.0 (down 405.14% YoY) and the FY2024 annual result came in at -$171254.0, down 405.14% from the prior year.
- Change in Receivables declined to -$117029.0 in Q2 2024, from -$54225.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $198087.0 in Q2 2022 to a low of -$506581.0 in Q2 2020.
- A 5-year average of -$56601.9 and a median of -$45874.5 in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2020 — Change in Receivables plunged 227.48% — and 2023, when it jumped 776.96%.
- Tracing SNGX's Change in Receivables over 5 years: stood at -$190628.0 in 2020, then surged by 149.68% to $94705.0 in 2021, then plunged by 116.48% to -$15612.0 in 2022, then soared by 773.86% to $105203.0 in 2023, then slumped by 211.24% to -$117029.0 in 2024.
- The last three Change in Receivables figures came in at -$117029.0 (Q2 2024), -$54225.0 (Q1 2024), and $105203.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -117,029.00 |
| Jun 30, 2024 | -117,029.00 |
| Mar 31, 2024 | -54,225.00 |
| Mar 31, 2024 | -54,225.00 |
| Dec 31, 2023 | 105,203.00 |
| Dec 31, 2023 | 105,203.00 |
| Sep 30, 2023 | -47,705.00 |
| Sep 30, 2023 | -47,705.00 |
| Jun 30, 2023 | -104,252.00 |
| Jun 30, 2023 | -104,252.00 |
| Mar 31, 2023 | 102,878.00 |
| Mar 31, 2023 | 102,878.00 |
| Dec 31, 2022 | -15,612.00 |
| Dec 31, 2022 | -15,612.00 |
| Sep 30, 2022 | -191,037.00 |
| Sep 30, 2022 | -191,037.00 |
| Jun 30, 2022 | 198,087.00 |
| Jun 30, 2022 | 198,087.00 |
| Mar 31, 2022 | -15,197.00 |
| Mar 31, 2022 | -15,197.00 |